Understand the source comparison
What's the Half-Life of AHK-Cu?: Comparison
AHK-Cu 45–90 minutes 6–12 hours (receptor-mediated effects) Twice daily (every 10–12 hours) Fast plasma clearance but extended biological activity. Dose based on receptor window, not blood levels GHK-Cu 60–75 minutes 8–14 hours Twice daily or once daily (highe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AHK-Cu
- 45–90 minutes
- 6–12 hours (receptor-mediated effects)
- Twice daily (every 10–12 hours)
- Fast plasma clearance but extended biological activity. Dose based on receptor window, not blood levels
- GHK-Cu
- 60–75 minutes
- 8–14 hours
- Twice daily or once daily (higher dose)
- Slightly longer tissue retention than AHK-Cu; single daily dosing viable at 2× dose
- BPC-157
- 4–6 hours
- 12–24 hours
- Once or twice daily
- Longer plasma half-life allows more flexible dosing schedules
- TB-500 (Thymosin Beta-4)
- 2–3 hours
- 24–48 hours
- Every 3–4 days
- Exceptionally long tissue retention. Infrequent dosing maintains therapeutic levels
- The table underscores a critical distinction: peptides with short plasma half-lives (AHK-Cu, GHK-Cu) require frequent administration to maintain continuous receptor activation, while peptides with longer tissue retention (TB-500) can be dosed less often. Protocol design must align with the peptide's mechanism. Dosing AHK-Cu every 72 hours because 'it saves peptide' negates the compound's efficacy entirely.